Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight ...
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...
A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.
One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...
Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...
A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...